Get the Stockscreener App
31.67
2.17%
1.05
Greenwich Lifesciences Inc stock is traded at $31.67, with a volume of 452.23K.
It is up +2.17% in the last 24 hours and up +51.24% over the past month.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
See More
Previous Close:
$30.62
Open:
$29.52
24h Volume:
452.23K
Relative Volume:
0.97
Market Cap:
$440.57M
Revenue:
-
Net Income/Loss:
$-8.89M
P/E Ratio:
-45.24
EPS:
-0.7
Net Cash Flow:
$-6.48M
1W Performance:
+46.95%
1M Performance:
+51.24%
6M Performance:
+170.40%
1Y Performance:
+135.58%
1-Day Range:
$29.00
$33.34
1-Week Range:
$20.00
$33.34
52-Week Range:
$7.78
$33.34
Greenwich Lifesciences Inc Stock (GLSI) Company Profile
Name
Greenwich Lifesciences Inc
Sector
Industry
Phone
203-434-3290
Address
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
Compare GLSI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLSI
Greenwich Lifesciences Inc
|
31.80 | 424.23M | 0 | -8.89M | -6.48M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.44 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
768.51 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
865.92 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
358.61 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
335.92 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Greenwich Lifesciences Inc Stock (GLSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-25 | Initiated | Noble Capital Markets | Outperform |
| Sep-01-21 | Initiated | H.C. Wainwright | Buy |
Greenwich Lifesciences Inc Stock (GLSI) Latest News
Greenwich LifeSciences reports $12.5 million cash balance - Investing.com
Greenwich Lifesciences Provides Update On Flamingo-01 Cash Burn Rate And Financing Strategy - TradingView
Biotech Greenwich LifeSciences raises $7M in 3 weeks for breast cancer trial - Stock Titan
Treasury Yields: Will Greenwich LifeSciences Inc benefit from current market trendsMarket Volume Report & Low Risk Entry Point Tips - baoquankhu1.vn
Greenwich: GP2 Vaccine MilestoneWhat FDA Manufacturing Approval Means For Investors - Seeking Alpha
Insiders of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) must be frustrated after market cap dropped US$50m since recent purchases - Yahoo Finance
Behavioral Patterns of GLSI and Institutional Flows - Stock Traders Daily
FDA approves commercial GP2 lot for Greenwich’s breast cancer trial By Investing.com - Investing.com Canada
Why Did Greenwich Lifesciences Stock Soar Pre-Market Today? - Mena FN
Why Did Greenwich LifeSciences Stock Soar Pre-Market Today? - Asianet Newsable
GLSI Stock Surges Pre-Market On Clearing FDA Manufacturing Step For Its Breast Cancer Trial - Stocktwits
Greenwich LifeSciences stock soars after FDA approves commercial GP2 in trial - Investing.com Canada
Greenwich gets FDA nod for commercially made product candidate - Seeking Alpha
Greenwich LifeSciences surges as FDA clears supplies for breast cancer trial - TradingView
Greenwich LifeSciences Announces FDA Approves Use of Commercially Manufactured GP2 in FLAMINGO-01 - The Manila Times
FDA approves first GP2 batch for breast cancer trial, 200,000 doses - Stock Titan
Head to Head Contrast: Greenwich LifeSciences (NASDAQ:GLSI) & Vertex Pharmaceuticals (NASDAQ:VRTX) - Defense World
Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Acquires 1,800 Shares of Stock - MarketBeat
Greenwich LifeSciences CEO Patel buys $53,694 in GLSI stock By Investing.com - Investing.com Canada
The $69B Precision Pivot: Why Biomarker Platforms are Igniting a New Oncology Gold Rush - Baystreet.ca
Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Purchases 2,900 Shares of Stock - MarketBeat
Greenwich LifeSciences CEO Patel buys $79,866 in GLSI stock By Investing.com - Investing.com South Africa
Greenwich LifeSciences CEO Patel buys $79,866 in GLSI stock - Investing.com
Greenwich LifeSciences (GLSI) Price Target Increased by 13.10% to 48.45 - Nasdaq
Chart Watch: Will Greenwich LifeSciences Inc stock benefit from commodity pricesJuly 2025 Reactions & Entry Point Confirmation Signals - Bộ Nội Vụ
Technical Analysis: Is Greenwich LifeSciences Inc stock ready for breakoutTrade Exit Summary & Reliable Price Action Trade Plans - Bộ Nội Vụ
Why is GLSI stock rising today? - MSN
HER2-Positive Breast Cancer Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Roche Pharma AG, Dizal Pharma, Greenwich LifeSciences, Ambrx - The Globe and Mail
Will Greenwich LifeSciences Inc. stock outperform growth indexesJuly 2025 Selloffs & Accurate Intraday Trading Signals - Улправда
Why Greenwich LifeSciences Inc. stock is a must watch in 2025Volume Weighted Average Price & Smart Beta Strategies That Actually Work - Улправда
How $594B in Precision Tech is Cracking the Metastatic Cancer Code - The Globe and Mail
Snehal Patel Buys Handful Of Shares In Greenwich LifeSciences - simplywall.st
Greenwich LifeSciences (NASDAQ:GLSI) CEO Snehal Patel Acquires 4,300 Shares - Defense World
Will Greenwich LifeSciences Inc. stock benefit from upcoming earnings reports2026 world cup usa national team group stage star players transition play group prediction preview - ulpravda.ru
A US$74m drop in the market cap of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) is not what insiders like to see after purchasing shares recently - simplywall.st
Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Acquires 4,300 Shares of Stock - MarketBeat
Head-To-Head Analysis: Greenwich LifeSciences (NASDAQ:GLSI) vs. Avalon GloboCare (NASDAQ:ALBT) - Defense World
Snehal Patel Purchases 2,900 Shares of Greenwich LifeSciences (NASDAQ:GLSI) Stock - Defense World
Is Lehar Footwears Limited Poised for a PostEarnings RallyVolatility Adjusted Trading & Free Exceptional Risk Adjusted Gains - earlytimes.in
Insider Buying: Snehal Patel Acquires Additional Shares of Green - GuruFocus
Patel, Greenwich Lifesciences CEO, buys $63k in GLSI stock By Investing.com - Investing.com Nigeria
Greenwich LifeSciences (NASDAQ:GLSI) CEO Snehal Patel Buys 2,900 Shares - MarketBeat
Patel, Greenwich Lifesciences CEO, buys $63k in GLSI stock - Investing.com
FY2025 Earnings Estimate for GLSI Issued By HC Wainwright - MarketBeat
How (GLSI) Movements Inform Risk Allocation Models - Stock Traders Daily
New milestone in breast cancer prevention claimed by Greenwich - The Pharma Letter
Greenwich LifeSciences stock soars after extending insider lock-up By Investing.com - Investing.com Australia
Greenwich LifeSciences extends insider share lock-up to Sept 2026 By Investing.com - Investing.com Nigeria
Greenwich LifeSciences stock soars after extending insider lock-up - Investing.com India
What's Going On With Greenwich LifeSciences Stock Monday? - One News Page
Greenwich Lifesciences Inc Stock (GLSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Greenwich Lifesciences Inc Stock (GLSI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Patel Snehal | CEO and CFO |
Jan 12 '26 |
Buy |
27.54 |
2,900 |
79,866 |
5,602,302 |
| Patel Snehal | CEO and CFO |
Dec 31 '25 |
Buy |
21.36 |
4,300 |
91,848 |
5,599,402 |
| Patel Snehal | CEO and CFO |
Dec 30 '25 |
Buy |
21.73 |
2,900 |
63,017 |
5,595,102 |
| Patel Snehal | CEO and CFO |
Dec 18 '25 |
Buy |
12.62 |
4,100 |
51,742 |
5,592,202 |
| Patel Snehal | CEO and CFO |
Nov 25 '25 |
Buy |
8.37 |
4,600 |
38,502 |
5,588,102 |
| Patel Snehal | CEO and CFO |
Nov 07 '25 |
Buy |
8.43 |
10,600 |
89,358 |
5,583,502 |
| Patel Snehal | CEO and CFO |
Oct 31 '25 |
Buy |
9.26 |
2,300 |
21,298 |
5,572,902 |
| Patel Snehal | CEO and CFO |
Apr 25 '25 |
Buy |
9.88 |
3,600 |
35,568 |
5,570,602 |
| Patel Snehal | CEO and CFO |
Apr 17 '25 |
Buy |
8.98 |
5,400 |
48,492 |
5,567,002 |
| Patel Snehal | CEO and CFO |
Apr 07 '25 |
Buy |
9.10 |
3,600 |
32,760 |
5,561,602 |
2.05%
0.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):